Leuprolide in Treating Adults With Hypogonadotropism
RATIONALE: Hypogonadotropism is an abnormal condition caused by decreased production of gonadotropins, a group of hormones that stimulate the parts of the reproductive system that produce and release eggs from the ovaries or sperm from the testicles. Leuprolide may stimulate the production of gonadotropins and be effective in increasing testosterone in men and inducing ovulation in women.
PURPOSE: Clinical trial to study the effectiveness of leuprolide in treating adults who have hypogonadotropism.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Study of Leuprolide in Adults With Hypogonadotropism|
|Study Start Date:||September 1997|
|Estimated Study Completion Date:||September 2002|
PROTOCOL OUTLINE: Male patients receive leuprolide subcutaneously every 5 days for up to one year and are followed at weeks 4, 6, 8, and 12, then every 2 months.
Female patients receive leuprolide subcutaneously on days 1, 6, and possibly 11. Patients are followed 2 months after the last injection.
Completion date provided represents the completion date of the grant per OOPD records
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004438
|United States, Illinois|
|University of Chicago Children's Hospital|
|Chicago, Illinois, United States, 60637|
|Study Chair:||Robert L. Rosenfield||University of Chicago|